Trial | NCT00293670  Report issue

Title

FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer
Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Indication/Condition

    Patients With T1-4 Advanced Prostate Cancer

  • Intervention/Treatment

    goserelin ...

  • Study Participants

    573
To compare intermittent androgen deprivation (LHRHa treatment) with continuous androgen deprivation (LHRHa treatment or orchidectomy)
Study Started
May 31
1997
Study Completion
Apr 30
2015
Last Update
Feb 17
2006
Estimate

Drug Goserelin (Zoladex)

Criteria 

• Inclusion Criteria (run-in period): T1-T4, metastatic (M1) prostate cancer T1-T4, non-metastatic (M0) prostate cancer with PSA > 60 ng/mL T3-T4, non-metastatic (M0) prostate cancer with PSA > 20ng/mL T1-T4, N+ prostate cancer WHO performance status 0-2 Written informed consent

• Inclusion criteria to the randomised period: Patients who fulfilled all entry criteria of the run-in period Patients who completed the 24-week run-in period Patients who responded to the 24-week run-in period with a decrease of PSA to < 10 ng/mL. If the baseline was < 20ng/mL, at least 50% decrease from the baseline measurement is required

Exclusion Criteria (run-in period):

Any previous or concurrent treatment of prostate cancer, except TURP, 5-alpha reductase inhibitor, radical prostatectomy or radiotherapy Any medication/treatment affecting sex hormone status

-
No Results Posted